Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation

Pediatric Blood and Cancer

Volumn 54, Issue 2, 2010, Pages 291-298

  Wall, Donna A ^a,j   Chan, Ka Wah ^b,k   Nieder, Michael L ^c,l   Hayashi, Robert J ^d   Yeager, Andrew M ^e,m   Kadota, Richard ^f   Przepiorka, Donna ^g   Mezzi, Khaled ^h   Kletzel, Morris ⁱ  

^a SAINT LOUIS UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Department of Pediatrics   (United States)

^d ST LOUIS CHILDREN S HOSPITAL   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j Manitoba Blood and Marrow Transplant Program   (Canada)

^k TEXAS TRANSPLANT INSTITUTE   (United States)

^l JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^m UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

Bone marrow transplantation; Children; Hematopoietic stem cell transplantation; Intravenous busulfan; Pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; N,N DIMETHYLACETAMIDE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUCOSIDOSIS; GLOBOID CELL LEUKODYSTROPHY; GRAFT VERSUS HOST REACTION; HUMAN; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; MALE; MANNOSIDOSIS; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; OSTEOPOROSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; SURVIVAL RATE; T CELL LYMPHOMA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; AREA UNDER CURVE; BUSULFAN; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 74849133514     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22227     Document Type: Article

References (44)

1. Dix SP,Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996;17:225-230.
2. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989;25:55-61.
3. Ljungman P, Hassan M, Bekassy AN, et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997;20:909-913.
4. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001;28:1013-1018.
5. Hoy SM, Lyseng-Williamson KA. Intravenous busulfan: In the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs 2007;9:271-278.
6. Nakamura H, Sato T, Okada K, et al. Population pharmacokinetics of oral busulfan in young Japanese children before hematopoietic stem cell transplantation. Ther Drug Monit 2008;30:75-83.
7. Grochow LB, Krivit W, Whitley CB, et al. Busulfan disposition in children. Blood 1990;75:1723-1727.
8. Hassan M, Fasth A, Gerritsen B, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996;18:843-850.
9. Hassan M, Oberg G, Bekassy AN, et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991;28:130-134.
10. Hassan M, Oberg G, Ehrsson H, et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989;36:525-530.
11. Vassal G, Gouyette A, Hartmann O, et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989;24:386-390.
12. Bolinger AM, Zangwill AB, Slattery JT, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000;25:925-930.
13. Bhagwatwar HP, Phadungpojna S, Chow DS, et al. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 1996;37:401-408.
14. Andersson BS, Gajewski J, Donato M, et al. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone MarrowTransplant 2000; 25:S35-S38.
15. Andersson BS, Madden T, Tran HT, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study. Biol Blood Marrow Transplant 2000; 6:548-554.
16. Slattery JT, Sanders JE,Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995;16:31-42.
17. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44:778-783.
18. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304.
19. Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 1995;14:357-379.
20. Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol 1996;14:296-303.
21. Porter PN. Effects of murine erythroleukemia inducers on mouse erythroid colony formation in culture. Differentiation 1979;15:57-60.
22. Sato C, Kojima K, Nishizawa K, et al. Early decrease in hyaluronidase-sensitive cell surface charge during the differentiation of Friend erythroleukemic cells by dimethyl sulfoxide. Cancer Res 1979;39:1113-1117.
23. Weiss AJ, Jackson LG, Carabasi RA, et al. A Phase I study of dimethylacetamide. Cancer Chemother Rep 1962;16:477-485.
24. Earhart RH, Koeller JM, Davis HL. Phase I trial of PCNU administered by 5-day courses. Cancer Treat Rep 1981;65:835-840.
25. Vassal G, Deroussent A, Challine D, et al. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992;79:2475-2479.
26. Vassal G, Koscielny S, Challine D, et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996;37: 247-253.
27. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002;8:477-485.
28. Ozkaynak MF,Weinberg K, Kohn D, et al. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: Incidence, risk factors, and clinical outcome. Bone Marrow Transplant 1991;7:467-474.
29. ShawPJ, Scharping CE, Brian RJ, et al. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994;84:2357-2362.
30. Yeager AM, Wagner JE, Jr., Graham ML, et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation. Blood 1992;80:2425-2428.
31. Booth BP, Rahman A, Dagher R, et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol 2007;47:101-111.
32. Vassal G, Michel G, Esperou H, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008;61:113-123.
33. Nguyen L, Fuller D, Lennon S, et al. I.V. busulfan in pediatrics: A novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone MarrowTransplant 2004;33:979-987.
34. Vaughan WP, Carey D, Perry S, et al. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002;8:619-624.
35. Dupuis LL, Najdova M, Saunders EF. Retrospective appraisal of busulfan dose adjustment in children. Bone Marrow Transplant 2000;26:1143-1147.
36. Kearns GL, Abdel-Rahman SM, AlanderSW, et al. Developmental pharmacology - Drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-1167.
37. Rodman JH, Murry DJ, Madden T, et al. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994;12:2390-2397.
38. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998; 20:543-549.
39. TranHT, Madden T, Petropoulos D, et al. Individualizing high-dose oral busulfan: Prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000;26:463-470.
40. Dalle JH, Wall D, Theoret Y, et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: Clinical and pharmacokinetic results. Bone Marrow Transplant 2003;32:647-651.
41. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hemopoietic stem cell transplantation for myelofibrosis. Blood 2003;102:3912-3918.
42. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003;102:31-35.
43. Tse WT, Duerst R, Schneiderman J, et al. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant 2009;44:145-156.
44. Lee JH, Choi SJ, Kim SE, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs. oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2004;84: 321-330.